Skip to content
★ Sign in to follow
Biofil Chemicals & Pharmaceuticals Limited logo

Biofil Chemicals & Pharmaceuticals Limited Stock: price and insider trades · India

IN·Mcap ₹524.5MHealth Care

No insider purchase over the last 90 days. The latest, by MEENA SHAH, was filed 20 Mar 2026.

Biofil Chemicals & Pharmaceuticals Limited: what insiders have been doing

Biofil Chemicals & Pharmaceuticals Limited belongs to the Health Care sector. Filings by its managers are published through SEBI (PIT + SAST). From 9 November 2025 to 9 November 2026, the disclosure feed for Biofil Chemicals & Pharmaceuticals Limited logged 2 filings by 2 insiders.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

There has been no open-market purchase by an insider of Biofil Chemicals & Pharmaceuticals Limited for at least a year.

Across the 1,985 companies tracked on its exchange, the median is 4 filings; at 2 filings, this issuer sits below that mark. Since 2021, the database holds 5 purchases and 3 sales by insiders of the company.

Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.

Insider Decl.
9
Thresholds
n/a
Buy Volume
n/a
5 ops. · all time
Sell Volume
n/a
3 ops. · all time

Who traded when

BuySale
Niyati Shah1 buy1 sale
Meena Shah1 buy
Fundamental score
Ranked 13,847 of 26,911 companies
50.7
score / 100
Value
45
Quality
56
FCF yld-1.6%
Earn yld5.7%
EV/EBITDA14.0x
ROE14%
Gross mgn8.6%
Net mgn9.8%
Debt/EBITDA0.8x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹32.23
Analyst consensus
·
Income statement
Revenue₹284M
Gross profit₹21.1M7% margin
EBITDA₹37.3M13% margin
Net income₹27.9M8.9% margin
Valuation
PER (trailing)18.8x
P/Book2.4x
Beta0.57
Balance sheet & cash
Market cap₹524.5M
Total debt₹30.2M
Free Cash Flow-₹8.1M
Debt / Equity14%
Profitability & ownership
ROE13.8%
ROA4.6%
% insiders58.1%
% institutions0.0%
Last declaration on 20 March 2026
Declarations9 total
  • ▲
    PromotersExecutives
    0SEBI
    32,657 sharesEquity SharesSEBI:6dcd7e5b974935aec698915cf545cbcaa6cdba35
    Canonical exit: 16 Jun 2026 (T+90)
  • ▼
    PromotersExecutives
    0SEBI
    32,657 sharesEquity SharesSEBI:58fc3cf4fccd04738056a826d1bb83b815f9c09d
  • ●
    -
    Executives
    0SEBI
  • ▲
    Executives
    0SEBI
    493,940 sharesEquity SharesSEBI:7c839c82e5ccb8ba47c61560bcf026e9d4239be0
    Canonical exit: 4 Sept 2025 (T+90)
  • ▲
    Executives
    0SEBI
    87,200 sharesEquity SharesSEBI:84b2f2c28bc7f091cc25537b17bed6bf431b4d3c
    Canonical exit: 9 Jun 2024 (T+90)
  • ▼
    Executives
    0SEBI
    87,200 sharesEquity SharesSEBI:3d294f85cc1835dcf6a77482eca4b8991c77059e
  • ▼
    Executives
    0SEBI
    300,000 sharesEquity SharesSEBI:dba95ca628068f3fb3ed926615028e82fcae45bd
  • ▲
    Executives
    0SEBI
    300,000 sharesEquity SharesSEBI:ccc1f575dc760d9a373728a303bd7fb6b62f10f4
    Canonical exit: 29 Jun 2022 (T+90)
  • ▲
    Executives
    0SEBI
    52,680 sharesEquity SharesSEBI:06c780a7d421cf8464a16556e647864bb8035d33
    Canonical exit: 30 Nov 2021 (T+90)

9 of 9 declarations

About Biofil Chemicals & Pharmaceuticals Limited

Biofil Chemicals & Pharmaceuticals Limited is a company specializing in the manufacture of chemical and pharmaceutical products. It is listed on the XBOM.